Zobrazeno 1 - 10
of 236
pro vyhledávání: ''
Autor:
Keisuke Watanabe, Yu Hara, Ayami Kaneko, Yoichi Tagami, Ho Namkoong, Nobuyuki Horita, Takeshi Kaneko, Nobuaki Kobayashi, Nobuhiko Fukuda, Kohei Somekawa
Publikováno v:
Thoracic Cancer, Vol 13, Iss 1, Pp 84-94 (2022)
Thoracic Cancer
Thoracic Cancer
Background Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related mortality worldwide. It is advisable to select the appropriate treatment based on characteristics of the cancer such as pathology, mutations, and programmed deat
Publikováno v:
Thoracic Cancer, Vol 13, Iss 2, Pp 257-264 (2022)
Thoracic Cancer
Thoracic Cancer
Background This study aimed to evaluate the inhibitory effects and potential mechanisms of icotinib combined with antiangiogenic drugs on lung adenocarcinoma in vivo. Methods A total of 72 mouse xenograft models established with human lung adenocarci
Autor:
Wenbo Liu, Yi Li, Xin Nie, Xu Li, Ping Zhang, Ailing Li, Bin Ai, Liming Wang, Yifan Yang, Shuai Zhang, Xiaonan Wu, Jiangyong Yu
Publikováno v:
Thoracic Cancer, Vol 13, Iss 1, Pp 31-37 (2022)
Thoracic Cancer
Thoracic Cancer
Background The aim of this study was to estimate the efficacy and safety of bevacizumab combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in advanced non‐small cell lung cancer (NSCLC) patients. Methods We search
Autor:
Yumei Peng, Yangchun Gu, Li Liang, Yan Zhang, Puyuan Xing, Haojing Li, Junling Li, Li Shan, Kewei Ma, Z. Zou, Guilan Dong, Xuezhi Hao, Cuiying Zhang, Ye Guo
Publikováno v:
Thoracic Cancer, Vol 13, Iss 1, Pp 107-116 (2022)
Thoracic Cancer
Thoracic Cancer
Background There is limited data on the clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in a real‐world setting for Chinese patients with advanced ALK+ NSCLC. Methods Th
Autor:
Xiaomin Huang, Xiang Ji, Pengfei Pan, Lisheng Xu, Qian Qi, Yu Li, Mingtao Liu, Fengjuan Wu, Zhiyun Xu, Peng Jiang, Ruyue Zhao
Publikováno v:
Thoracic Cancer, Vol 12, Iss 24, Pp 3416-3425 (2021)
Thoracic Cancer
Thoracic Cancer
Background The aim of the study was to assess the efficacy and side‐effects of intrapleural treatment in non‐small cell lung cancer (NSCLC) patients with malignant pleural effusions (MPEs). Methods The medical records of NSCLC patients with MPEs
Publikováno v:
Thoracic Cancer. 12:3340-3355
Background Chemoresistance is a major barrier limiting the therapeutic efficacy of late stage non-small cell lung cancer (NSCLC). In this study, we sought to use two-dimensional titanium carbide (2D Ti2 C) to reverse cisplatin resistance in NSCLC. Me
Publikováno v:
Thoracic Cancer, Vol 12, Iss 21, Pp 2894-2906 (2021)
Thoracic Cancer
Thoracic Cancer
Background Drug resistance is a major clinical drawback behind the failure of chemotherapy in non‐small cell lung cancer (NSCLC). In this study, we undertook to identify the precise role of circular RNA (circRNA) circ_0058357 in the functional prop
Autor:
Chin-Chou Wang, Chien-Hao Lai, Meng-Chih Lin, Huang-Chih Chang, Chia-Cheng Tseng, Kuo-Tung Huang, Yu-Ping Chang
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 23, Pp 3263-3272 (2021)
Thoracic Cancer, Vol 12, Iss 23, Pp 3263-3272 (2021)
Purpose To investigate the survival benefit with first/second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) and osimertinib in different treatment sequences. Methods We retrospectively screened 3807 patients dia
Autor:
Mai Matsumura, Hiroaki Fujii, Makiko Enaka, Katsushi Tanaka, Maki Hagihara, Ayami Kaneko, Keisuke Watanabe, Kohei Somekawa, Yoichi Tagami, Kenichi Seki, Yu Hara, Ami Izawa, Nobuyuki Horita, Nobuaki Kobayashi, Miki Hoshi, Ayako Aoki, Takeshi Kaneko
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 23, Pp 3281-3285 (2021)
Thoracic Cancer, Vol 12, Iss 23, Pp 3281-3285 (2021)
Lung lesions of Hodgkin's lymphoma (HL) are rare and difficult to diagnose by nonsurgical biopsy. We herein present the case of a 72‐year‐old Japanese male who presented with accumulation of lung infiltrates and masses bilaterally on the lungs fo
Autor:
Ryo Ko, Ryo Koyama, Keita Miura, Mikiko Mori, Tetsuhiko Asao, Hiroaki Motomura, Koichi Nishino, Takuo Hayashi, Kazuhisa Takahashi, Motoyasu Kato
Publikováno v:
Thoracic Cancer, Vol 12, Iss 22, Pp 3076-3079 (2021)
Thoracic Cancer
Thoracic Cancer
Immune checkpoint inhibitors can often trigger immune‐related adverse events (irAEs), such as relapse of pre‐existing interstitial pneumonia. Here, we report the case of an 88‐year‐Japanese man diagnosed with advanced lung adenocarcinoma with